Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ThromboGenics Announces Publication of New England Journal of Medicine Paper

Published: Saturday, September 15, 2012
Last Updated: Saturday, September 15, 2012
Bookmark and Share
Paper highlights that ocriplasmin is superior to placebo in resolving VMT and closing macular holes in patients with VMA.

ThromboGenics NV has announced that the data from two Phase III clinical trials evaluating ocriplasmin for the treatment of vitreomacular traction (VMT) and macular holes will be published in the New England Journal of Medicine on 16 August 2012.

The paper highlights that a single intravitreal injection of ocriplasmin resolved Vitreomacular Adhesion (VMA), releasing traction and closing macular holes in significantly more patients than placebo.

VMT is also referred to as symptomatic Vitreomacular Adhesion.

The two multicenter, randomized, double-blind Phase III trials with ocriplasmin were conducted in the U.S. and Europe and involved 652 patients with VMA.

Both studies met the primary endpoint of pharmacological resolution of VMA at day 28. Secondary endpoints included nonsurgical closure of a macular hole at 28 days, avoidance of vitrectomy (surgery) and improvement in visual acuity.

The Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.001).

Nonsurgical closure of macular holes occurred in 40.6% of ocriplasmin-treated patients, compared with 10.6% of patients on placebo (p<0.001).

Patients given ocriplasmin were more likely to achieve a vision gain of at least three lines compared with placebo. Treatment with ocriplasmin was associated with some, mainly transient ocular adverse events.

Dr Patrik De Haes, CEO of ThromboGenics, said: “The publication of the data from our pivotal Phase III trials with ocriplasmin in this prestigious peer-reviewed journal highlights the potential of this novel pharmacological approach for the treatment of VMA and associated VMT. Following the FDA advisory panel’s decision last month to recommend ocriplasmin for the treatment of symptomatic VMA, we are continuing to work closely with the Agency so that we can make ocriplasmin available to patients in the U.S. if approved.”

Dr Julia Haller, Ophthalmologist-in-Chief of the Wills Eye Institute, and Professor and Chair of the Department of Ophthalmology at Thomas Jefferson University, said: “This New England Journal of Medicine paper highlights data showing ocriplasmin’s potential to become the first pharmacological option for the treatment of symptomatic VMA and macular holes. An in-office injection would be a new and possibly earlier alternative treatment for the vitreoretinal surgeon to offer to patients with these sight threatening disorders. Ocriplasmin represents a potential new treatment paradigm for the retina community and for our patients with VMA and macular holes.”

ThromboGenics has made regulatory filings for ocriplasmin in both the U.S. and Europe. Last month, an FDA advisory panel recommended the approval of ocriplasmin for the treatment of symptomatic VMA.

If approved, the Company plans to commercialize ocriplasmin itself in the U.S. In Europe ocriplasmin is currently under regulatory review by the European Medicines Agency (EMA).

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States.

Kevin Buehler, Division Head, Alcon, said: “The data published in the NEJM have formed a key part of the ocriplasmin European Marketing Authorization Application that is currently under review by the EMA. With Alcon’s extensive commercial capabilities, geographic footprint and strong relationships with retinal specialists and ophthalmologists, we are well positioned to bring what we believe is a truly innovative treatment option to patients suffering from VMT and macular holes in Europe and other countries outside the United States.”

Symptomatic VMA or VMT is a progressive condition that if left untreated frequently leads to retinal distortion, further deterioration in vision and has the potential to cause irreversible damage and complications.

Market research conducted by ThromboGenics suggests that there are approximately 500,000 patients in the U.S. and the major EU markets who could potentially benefit from ocriplasmin annually. If approved, ocriplasmin will be the first pharmacological treatment for symptomatic VMA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ThromboGenics Announces FDA Acceptance of IND Application
FDA acceptance for Phase II study with JETREA® for the treatment of non-proliferative diabetic retinopathy (CIRCLE).
Tuesday, November 24, 2015
ThromboGenics and VIB Launch New Oncology Company
Oncurious NV to develop TB-403 for pediatric brain tumors.
Tuesday, April 14, 2015
ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA® in the US
ORBIT study designed to generate further data on the “real world” use of JETREA®.
Thursday, March 06, 2014
ThromboGenics Appoints Dr David Guyer to its Board of Directors
Dr Guyer is currently the Co-Founder and Chief Executive Officer of Ophthotech Corporation.
Monday, December 23, 2013
ThromboGenics Business Update
US sales through end of April 2013 have exceeded $10 million.
Monday, May 27, 2013
ThromboGenics Receives Positive CHMP Opinion for JETREA®
Positive opinion clears the way for the potential EMA approval of JETREA® as the first pharmacological option for the treatment of VMT, including when associated with macular hole of diameter less than or equal to 400 microns.
Wednesday, April 24, 2013
ThromboGenics NV - Business Update
Company to build a first-class US commercial organization to launch JETREA in January 2013.
Friday, November 09, 2012
ThromboGenics NV - Business Update
ThromboGenics sign an important strategic deal with Alcon.
Monday, October 22, 2012
U.S. FDA Approves ThromboGenics’ JETREA® (Ocriplasmin)
JETREA® is the first pharmacological agent approved for the treatment of symptomatic VMA.
Thursday, October 18, 2012
ThromboGenics and BioInvent Announce Results from Phase IIb VTE Prevention Study with TB-402
All further development of TB-402 will be stopped.
Thursday, July 05, 2012
ThromboGenics and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 Ahead of Schedule
The companies announced they have completed the enrolment of a 632-patient Phase IIb trial with their long-acting anticoagulant TB-402 (factor VIII inhibitor).
Friday, December 16, 2011
ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for VMA
Highly significant trial result demonstrates the potential of microplasmin in the treatment of retinal disease.
Monday, April 26, 2010
ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
ThromboGenics NV announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME). The data from this trial were presented at the ASRS (American Society of Retina Specialists) Conference in New York on 3 October, 2009 by Professor Peter Stalmans, University Hospitals Leuven, Belgium.
Friday, October 09, 2009
ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of DME
The MIVI II DME trial is a Phase II clinical trial evaluating the safety and initial efficacy of intravitreal microplasmin for the treatment of DME patients.
Monday, March 09, 2009
Scientific News
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!